CRSP CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Three June Conferences

CRISPR Therapeutics to Participate in Three June Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in June 2018.

The 2018 BIO International Convention

Panel: Advances in Genome Editing – The Next Frontier in Human Health

Date: Wednesday, June 6, 2018

Presentation: 1:45 – 2:45 PM EST

Location: Room 210 B, Level 2, Boston Convention and Exhibition Center

Goldman Sachs 39th Annual Global Healthcare Conference

Date: Wednesday, June 13, 2018

Fireside Chat: 8:00 – 8:35 AM PST

Location: Terranea Resort, Rancho Palos Verdes, CA.

The JMP 2018 Securities Life Sciences Conference

Panel: Gene Editing: From Science to Reality

Date: Wednesday, June 20, 2018

Presentation: 8:00 – 8:50 AM EST

Location: The St. Regis Hotel, New York, NY

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit .

MEDIA CONTACT:

Jennifer Paganelli

WCG on behalf of CRISPR

 

INVESTOR CONTACT:

Chris Erdman

+1 617.307.7227  

Chris Brinzey

Westwicke Partners for CRISPR

 

EN
05/06/2018

Underlying

CRSPCRISPR Therapeutics AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRISPR Therapeutics AG

 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarte...

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and pr...

February 12, 2026 1 EN
Free Trial
CRSP CRISPR Therapeu...

CRISPR Therapeutics AG: 1 director

A director at CRISPR Therapeutics AG sold 90,000 shares at 57.403USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

CRSP CRISPR THERAPEUTICS AG
01/23/26 January 23, 2026 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 20...

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones  -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Na...

January 12, 2026 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthca...

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT in San Francisco. A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of ...

January 5, 2026 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Z...

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary imm...

December 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch